US Patent 7,651,698: Claim Scope, Exclusivity, Litigation Risk, and Patent Landscape for Bioadhesive Miconazole Tablets

US Patent 7,651,698 protects a narrow buccal drug-delivery combination rather than miconazole itself. Its core requirements are a bioadhesive therapeutic system for treating buccal candidiasis, an azole antifungal, sustained dissolution exceeding 70% over eight hours, natural proteins, a hydrophilic polymer, specified surfactant and sugar ranges, and compression excipients. The strongest commercial embodiment is a 50-mg miconazole buccal tablet containing sodium lauryl sulfate, a natural-protein bioadhesive matrix, hydrophilic polymer, and lactose monohydrate or sucrose.

The patent does not broadly cover every miconazole oral formulation, every treatment of candidiasis, or every mucoadhesive dosage form. Infringement generally requires satisfaction of every limitation in an asserted claim.

What does US Patent 7,651,698 protect?

US Patent 7,651,698 protects methods of treating buccal candidiasis by administering a defined bioadhesive therapeutic system. The claims combine therapeutic-use limitations with detailed composition and performance limitations.

Claim feature	Scope
Disease	Buccal candidiasis
Administration	Administration to a patient in need
Dosage form	Bioadhesive therapeutic system; claim 3 expressly refers to a tablet
Active ingredient	Broad-spectrum azole antifungal; dependent claims focus on miconazole
Dissolution	More than 70% active-principle dissolution over eight hours
Natural proteins	At least 50% by weight of active principle and at least 20% by weight of the therapeutic system
Hydrophilic polymer	10% to 20%
Alkali metal alkylsulfate	3.5% to 10%
Monohydrate sugar	0.1% to 1%
Compression excipients	Required, with corn starch specified in claim 5
Miconazole dose	10 to 150 mg; narrower ranges of 25 to 75 mg and 50 mg
Preferred surfactant	Sodium lauryl sulfate at 4% to 6% in narrower claims

The claim set is drafted as a formulation-defined method patent. A product that contains miconazole but lacks the claimed bioadhesive matrix, surfactant concentration, dissolution profile, or treatment use would not literally satisfy the full combination.

What is the independent-claim structure?

Claims 1, 11, 12 and 17 are the principal independent claims.

Claim 1 is the broadest formulation-and-treatment claim. It covers any listed broad-spectrum azole, provided that the system satisfies the protein, polymer, dissolution, surfactant, sugar and compression-excipient limitations.

Claim 11 narrows the active ingredient and excipient alternatives by expressly requiring one of the listed azoles, sodium lauryl sulfate or diethylsulphosuccinate, and sucrose or lactose monohydrate.

Claim 12 focuses on miconazole but retains the alternative alkali metal alkylsulfate and monohydrate-sugar language.

Claim 17 is the commercially most specific claim. It requires:

miconazole;
50 mg per bioadhesive therapeutic system;
more than 70% dissolution over eight hours;
natural proteins at the specified levels;
10% to 20% hydrophilic polymer;
3.5% to 10% sodium lauryl sulfate; and
0.1% to 1% monohydrate sugar.

A competing 50-mg miconazole buccal tablet would face the greatest literal-infringement risk under claim 17 if it reproduced the same excipient architecture and dissolution profile.

How should the disputed claim language be interpreted?

Several limitations are commercially important and may create validity or infringement disputes.

“Natural proteins representing at least 50% by weight of active principle”

This language appears to define the amount of natural protein relative to the active ingredient, not necessarily 50% of the finished dosage form. If the system contains 50 mg of miconazole, the claim requires at least 25 mg of natural protein under a straightforward weight-ratio interpretation.

The claim also requires natural proteins to represent at least 20% by weight of the bioadhesive therapeutic system. Both thresholds must be satisfied. A formulation containing a protein at 20% of total tablet weight but less than 50% of the active-ingredient weight could fall outside the claim.

The specification and prosecution history would be important in determining whether “natural proteins” includes specific proteins such as gelatin, collagen, casein or other proteinaceous materials, and whether mixtures qualify.

“More than 70% over 8 hours”

This is a performance limitation. It requires a dissolution result above 70% at or over the specified eight-hour period under the test method applicable to the patent.

The dissolution method matters. A product could produce different results under USP apparatus, agitation rate, medium, pH, sampling intervals or analytical method. For enforcement, the patent owner would likely need validated testing tied to the patent’s disclosure and claim construction.

“Between” percentage ranges

The surfactant and polymer limitations are numerical restrictions. A formulation with 3.49% sodium lauryl sulfate would be outside the literal 3.5% to 10% range, subject to measurement tolerances and possible doctrine-of-equivalents arguments. A formulation with 11% hydrophilic polymer would be outside the literal 10% to 20% range.

The narrow 4% to 6% sodium lauryl sulfate limitation in claims 10 and 16 creates a more concentrated infringement target than the 3.5% to 10% range in the independent claims.

“Micoazole”

Claims 7 and 13 use “micoazole,” while the surrounding claims and the disclosed active ingredient identify miconazole. The apparent typographical error would normally be evaluated against the specification, prosecution record and skilled-person understanding. It is unlikely to create a commercially meaningful escape route where the formulation plainly contains miconazole.

What formulations are protected by US 7,651,698?

The most clearly protected formulation is a sustained-release, mucoadhesive miconazole tablet for buccal candidiasis.

Formulation variable	Broad claimed range	Narrow commercial focus
Miconazole dose	10 to 150 mg	50 mg
Natural proteins	At least 50% of active weight; at least 20% of system weight	Protein-based mucoadhesive matrix
Hydrophilic polymer	10% to 20%	Within the claimed range
Sodium lauryl sulfate	3.5% to 10%	4% to 6%
Monohydrate sugar	0.1% to 1%	Lactose monohydrate or sucrose
Dissolution	More than 70% over eight hours	Sustained buccal delivery
Dosage form	Bioadhesive therapeutic system	Tablet

The claims also cover alternative azoles, including clotrimazole, ketoconazole, fluconazole, itraconazole, econazole, terconazole, tioconazole and sertaconazole. That breadth is limited by the requirement that the product be used to treat buccal candidiasis and satisfy the same formulation-performance architecture.

Does the patent cover miconazole itself?

No. Miconazole is a long-established active ingredient, and US 7,651,698 does not claim the molecule, its basic antifungal activity, or all pharmaceutical uses.

The patent claims a particular delivery system and treatment method. A conventional oral gel, lozenge, suspension, cream, vaginal product, injectable product or unformulated miconazole product would not fall within the claims merely because it contains miconazole.

The patent also does not necessarily cover every buccal miconazole product. A competing formulation could reduce risk by changing one or more required elements, such as:

using a nonprotein mucoadhesive;
omitting sodium lauryl sulfate;
using a surfactant outside the claimed range;
using a sugar other than sucrose or lactose monohydrate;
using a hydrophilic polymer concentration outside 10% to 20%;
using a different dissolution profile; or
selecting a non-azole antifungal.

A design-around analysis must account for literal infringement and potential equivalents. Changing an ingredient may not eliminate risk if the substitute performs substantially the same function in substantially the same way to obtain substantially the same result.

What is the FDA and Orange Book status?

The patent is associated with the Oravig product, a 50-mg miconazole buccal tablet approved by the FDA for local treatment of oropharyngeal candidiasis in adults and children age 16 and older. Oravig was approved under NDA 022181. The product’s dosage form and 50-mg miconazole strength correspond closely to the narrower claims of US 7,651,698. [2]

The relevant regulatory distinction is between:

FDA approval of the product;
Orange Book listing of patents submitted for the approved drug; and
enforceability or current term of the patent.

An Orange Book listing does not independently establish validity. It identifies patents submitted by the NDA holder as covering the approved drug or an approved method of use. The current Orange Book entry and FDA patent-listing records should control the operative listing status and expiration information. [3]

What exclusivity did Oravig receive?

Oravig was approved as a new drug product containing an established active ingredient in a novel buccal delivery system. Its commercial protection depended primarily on patent rights rather than long-term new chemical entity exclusivity for miconazole.

Regulatory exclusivity and patent term are separate. FDA approval does not extend a patent automatically. Conversely, a patent may remain in force after FDA exclusivity ends, subject to its statutory term, patent-term adjustment, patent-term extension and any terminal disclaimer. [1, 3]

When does US Patent 7,651,698 lose exclusivity?

The patent’s operative expiration date cannot be established from the claim text alone. Patent term must be calculated from the effective US filing and priority chain, then adjusted for patent-term adjustment, any patent-term extension under 35 U.S.C. § 156, and terminal disclaimers. The controlling records are the USPTO patent file and the FDA Orange Book entry for the approved product. [1, 3]

The grant date is not the expiration date. For a post-1995 US patent, the ordinary term is generally 20 years from the earliest effective nonprovisional US or international application date, not 20 years from issuance. [1]

For business planning, the relevant date is the later of:

the patent expiration date recorded by the USPTO;
any applicable patent-term extension;
the enforceable scope after claim construction and validity review; and
the status of any Orange Book-listed method-of-use patent or later continuation.

A generic or authorized-generic launch assessment should not rely on the grant date or on a simple 20-year calculation.

How strong is the patent estate for Oravig?

The estate is strongest against a direct copy of the approved 50-mg miconazole buccal tablet. Claim 17 aligns closely with that product profile and reduces the number of factual disputes over active ingredient, dose and excipient selection.

Its principal vulnerabilities are technical and legal:

Issue	Risk to patent owner
Prior art	Earlier mucoadhesive tablets, protein matrices, azole formulations and sustained-release systems could challenge novelty or obviousness
Claim construction	Ambiguity in protein-to-active weight ratios and dissolution language
Written description	Breadth across many azoles and excipient alternatives may be tested against the specification
Enablement	The patent must support the full scope of the azole and formulation genus
Method limitation	A product claim may be easier to design around if the accused product is not labeled or used for buccal candidiasis
Numerical ranges	Formulators can target concentrations outside the claimed ranges
Typographical language	“Micoazole” in claims 7 and 13 may require prosecution-history interpretation

The estate is weaker against a product that uses a different bioadhesive mechanism, a different active ingredient, a non-tablet delivery system or a materially different dissolution profile.

What Paragraph IV challenges could target this patent?

A generic applicant seeking approval for a product referencing Oravig could address the patent through an Abbreviated New Drug Application and certify under Paragraph IV that the patent is invalid, unenforceable or not infringed. The likely theories would include:

the proposed product does not contain the required protein level;
the hydrophilic polymer is outside the claimed range;
sodium lauryl sulfate or another alkylsulfate is absent or outside the range;
the sugar limitation is not met;
the dissolution profile is not above 70% over eight hours;
the proposed use does not correspond to treatment of buccal candidiasis; or
the claims are invalid for obviousness in view of mucoadhesive buccal delivery and known azole antifungal formulations.

A Paragraph IV notice would create a potential Hatch-Waxman infringement action under 35 U.S.C. § 271(e)(2). A timely action can trigger a 30-month FDA approval stay, subject to statutory exceptions and court rulings. [4]

No conclusion about a specific Paragraph IV challenge, litigation filing, settlement or launch date follows from the claims supplied. Those events require review of FDA ANDA records, public court dockets and the patent’s prosecution file.

Which companies are challenging US 7,651,698?

The supplied material identifies no challenger, ANDA applicant, litigation defendant or settlement party. The patent number and claim text alone do not establish a current Paragraph IV challenge or active litigation.

The relevant commercial parties historically associated with the product include the patent owner or originating developer, BioAlliance Pharma, later associated with Onxeo, and US commercialization partners for Oravig. Corporate ownership, licensing and commercialization arrangements may have changed over time and should be separated from patent ownership recorded by the USPTO. [2, 5]

Does biosimilar risk apply?

No. Biosimilar regulation is not the relevant pathway because miconazole is a chemically synthesized small molecule, not a biological product regulated through the biosimilar framework under the Public Health Service Act.

The relevant competitive threats are:

ANDA-approved generic miconazole buccal tablets;
authorized generics;
505(b)(2) products using a modified buccal delivery system;
compounded formulations; and
alternative local antifungal products.

A 505(b)(2) applicant could pursue a modified dosage form or clinical use while addressing patent claims through certification or litigation strategies applicable to the listed patents.

What manufacturing and IP barriers remain?

The technical barrier is not miconazole synthesis. It is reproducible manufacture of a tablet that simultaneously provides:

adequate adhesion to the buccal mucosa;
controlled residence time;
acceptable taste and mouthfeel;
mechanical strength;
uniform distribution of protein and polymer;
stable surfactant and sugar content;
consistent dissolution above the claimed threshold; and
acceptable microbial and chemical stability.

The patent may therefore have greater practical value than its narrow claim language suggests. A design-around can avoid literal infringement but still require substantial formulation development, scale-up work and clinical or regulatory bridging.

Manufacturing know-how may include granulation conditions, compression force, particle-size control, protein handling, moisture control, coating, packaging and dissolution-test parameters. Those process elements are not necessarily disclosed or protected by US 7,651,698 and may be maintained as trade secrets or covered by separate patents.

How does US 7,651,698 compare with ordinary miconazole products?

Product category	Likely relationship to US 7,651,698
50-mg miconazole buccal tablet with claimed excipients	Highest risk
Miconazole oral gel	Generally outside the claimed tablet-specific embodiment; method claims still require the claimed system
Miconazole lozenge without protein matrix	Likely outside literal scope if protein limitation is absent
Clotrimazole troche	Potentially relevant only if all formulation and use limitations are met
Miconazole vaginal or dermatological product	Outside the buccal-candidiasis treatment requirement
Non-azole buccal antifungal	Outside claims limited to listed azoles
Protein-free mucoadhesive tablet	Strong design-around position, subject to equivalents
Tablet with no sodium lauryl sulfate or diethylsulphosuccinate	Strong design-around position against claims requiring those excipients

Key Takeaways

US Patent 7,651,698 is a formulation-and-method patent, not a basic miconazole patent.
Its core scope is a bioadhesive buccal system for treating buccal candidiasis.
The highest-risk commercial copy is a 50-mg miconazole tablet with natural proteins, 10% to 20% hydrophilic polymer, 3.5% to 10% sodium lauryl sulfate, 0.1% to 1% lactose monohydrate or sucrose, and dissolution above 70% over eight hours.
Claims 1, 11, 12 and 17 are the principal independent claims.
The most material claim-construction issues concern the protein-to-active ratio, dissolution test, numerical ranges and the “micoazole” typographical error.
Miconazole generics are not biosimilars. The relevant pathways are ANDA and, for modified products, 505(b)(2).
A current expiration date, Orange Book status, Paragraph IV challenge or litigation position must be determined from USPTO, FDA and court records rather than from the claim text.
A formulation that changes the protein matrix, surfactant, polymer range, sugar, dissolution profile or dosage form may reduce literal-infringement risk, but doctrine-of-equivalents exposure remains relevant.

FAQs

Can a miconazole buccal tablet avoid US 7,651,698 by using sodium stearate instead of sodium lauryl sulfate?

Potentially. Sodium stearate is not one of the expressly identified alkali metal alkylsulfates. The formulation would still require analysis under the doctrine of equivalents and against any other applicable patent.

Does a 50-mg dose alone infringe US 7,651,698?

No. The 50-mg dose is only one limitation in the narrow claims. The accused product must also satisfy the bioadhesive, protein, polymer, surfactant, sugar, compression-excipient, dissolution and treatment-use limitations.

Could a miconazole buccal film infringe the patent?

Yes, in principle, if it qualifies as the claimed “bioadhesive therapeutic system” and satisfies every other limitation. The claims are not uniformly limited to conventional compressed tablets, although claim 3 and related dependent claims expressly address tablets.

Is lactose monohydrate required in every claimed formulation?

No. The claims permit alternatives, including lactose monohydrate or sucrose. Some claims also permit alternative alkali metal alkylsulfates, including sodium lauryl sulfate and diethylsulphosuccinate.

Does FDA approval of Oravig prove that every claim of US 7,651,698 is valid?

No. FDA approval and Orange Book listing do not adjudicate patent validity, enforceability or infringement. Those issues are determined under patent law and, when litigated, by the courts.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension information. https://www.uspto.gov
U.S. Food and Drug Administration. (2010). Oravig (miconazole) buccal tablets prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Code, 35 U.S.C. §§ 156, 271(e)(2), 355(j).
U.S. Patent and Trademark Office. (2010). US Patent No. 7,651,698, Bioadhesive therapeutic system for the treatment of buccal pathologies.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 09811	Jul 23, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	373464	⤷ Start Trial
Austria	411003	⤷ Start Trial
Canada	2455633	⤷ Start Trial
China	101524337	⤷ Start Trial
China	1547464	⤷ Start Trial
Cyprus	1107828	⤷ Start Trial
Cyprus	1108796	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,651,698

Summary for Patent: 7,651,698